WEN's fourth-quarter fiscal 2024 results reflect solid comps growth and increased average checks. Dive in to learn more about the quarter's...

AL's fourth-quarter 2024 earnings were hurt by higher interest expense, driven by the increase in its composite cost of funds and overall outstanding...

RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.

LPX's fourth-quarter results reflect solid demand trends in the Siding business, partially offset by soft contributions from the OSB segment.

FLS' fourth-quarter 2024 revenues increase 1.3% year over year, driven by the impressive performance of its Flowserve Flow Control Division unit.

ATUS reported a top-line contraction year over year in the fourth quarter of 2024, owing to declining net sales in multiple segments.

H's fourth-quarter 2024 results are hurt by the timing shift of the Jewish holidays and the U.S. election in November.

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement.

AVNT's fourth-quarter organic sales rise 5% year over year aided by growth in all geographic regions.

LECO's Q4 top line reflects the impacts of a decrease in organic sales and unfavorable foreign exchange, partially offset by acquisitions.